DMRADamora Therapeutics, Inc.
What is the market doing?
No clear lean: insiders net buying, but heavily shorted (+14% of shares).
Rangebound, no clear trend. Price is −19% vs its 200-day average.
Insiders were net buyers over the 90 days ending Oct 9, 2026.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover. Level with the previous count, up from 10.4% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How DMRA is trading
Damora Therapeutics, Inc. is +636% over the past year while the S&P 500 is +18%: 618 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −19%
vs 200-day average · a clear downtrend
- RSI (14)
- 39
RSI (14) · neutral
- Below its 52-week high
- 38%
Below its 52-week high
Details›
- Last close2026-10-09
- $21.12
- 1 monthS&P 500 +2.7%
- −21%
- 1 yearS&P 500 +18%
- +636%
- 5 yearsS&P 500 +88%
- −80%
- vs 50-day average$26.52
- −20%
- 52-week high
- $34.14
- 52-week low
- $3.00
- Annualised volatility
- 343%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-09
- $246K
| Year | Return |
|---|---|
| 2026 (year to date) | −8.2% |
| 2025 | +395% |
| 2024 | −74% |
| 2023 | −37% |
| 2022 | −62% |
| 2021 | −76% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | +14% |
| Feb | 6 | 2 of 6 | −4.2% |
| Mar | 6 | 2 of 6 | −11% |
| Apr | 6 | 0 of 6 | −11% |
| May | 6 | 2 of 6 | −1.5% |
| Jun | 6 | 3 of 6 | +3.8% |
| Jul | 6 | 3 of 6 | +7.7% |
| Aug | 6 | 2 of 6 | −11% |
| Sep | 6 | 3 of 6 | −3.1% |
| Oct | 6 | 2 of 6 | +4.0% |
| Nov | 6 | 3 of 6 | +17% |
| Dec | 6 | 3 of 6 | −1.0% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.